XALute randomises about 675 men 2:1 with OS as the primary endpoint; it was active and no longer recruiting in May 2026. The companion XALience trial tests xaluritamig + abiraterone in chemo-naive mCRPC.
Setting
mCRPC after ARPI and taxane: xaluritamig vs cabazitaxel or second ARPI (investigator's choice; ≥50% cabazitaxel)
Phase
Phase 3
Sponsor
Amgen
Registry
Enrolled
675
Replication
Ongoing phase 3 of xaluritamig vs cabazitaxel/ARPI; no results.
Pages like this
not linked directly; found by shared links- TermPSA50 / PSA90 response
Shares Xaluritamig, Prostate cancer.
- PersonOwen N. Witte
Shares STEAP1, Prostate cancer.
- TrialTheraP (ANZUP 1603)
Shares Cabazitaxel, Prostate cancer.
- CompanyAmgen
Shares Xaluritamig, Prostate cancer.